États-Unis · Bourse & Finance · Morningstar

Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026

Publié par Morningstar · États-Unis il y a 9 h

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in ...

Lire l'article complet sur Morningstar Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.morningstar.com)

Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026

À lire aussi

White House Filing Claims President Has Authority to Bar News Outlets

Power Play

Oil prices drop as G7 nations pledge to release diesel stocks; Saudis said planning attack on Houthis

Mark Ruffalo says Paramount’s $111 billion Warner Bros. deal ‘Will stifle creativity, weaken free speech, and cost people their jobs’

OpenAI safety leader David Robinson resigns as the team's upheaval mounts

Cerebras stock hits post-IPO low, tumbling 20% for the week on Nvidia pressure and lockup expiration

Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026

Partager

À lire aussi

White House Filing Claims President Has Authority to Bar News Outlets

Power Play

Oil prices drop as G7 nations pledge to release diesel stocks; Saudis said planning attack on Houthis

Mark Ruffalo says Paramount’s $111 billion Warner Bros. deal ‘Will stifle creativity, weaken free speech, and cost people their jobs’

OpenAI safety leader David Robinson resigns as the team's upheaval mounts

Cerebras stock hits post-IPO low, tumbling 20% for the week on Nvidia pressure and lockup expiration